Introduction
associated with molecular changes suggesting a transition from a vulnerable to a more stable plaque phenotype [10] . The 
Methods

In vivo study Study design
Abdominal aortic atherosclerotic plaques were induced in rabbits (n ϭ 16) by a combination of 9-month 0.2% cholesterol-rich diet plus two aortic denudations as previously described [11, 12] Health, 1996. 
. At the end of the atherosclerosis induction period, animals were randomized to receive two intravenous (i.v.) injections, 4 days apart, of recombinant ApoA-IMilano (rApoA-IM)-phospholipids (n ϭ 8) or equal volume of placebo (saline, n ϭ 8) [10]. Four days after the last dose, animals were killed and the aortas and livers were harvested and processed for lipid content measurement, atherosclerotic plaque oxidative stress, as well as for gene and protein expression of markers involved in RCT and inflammation. Plasma from animals receiving rApoA-IM was collected immediately before the first dose and at sacrifice for determination of systemic cholesterol levels, systemic lipid peroxidation products and prostaglandin F1-␣ (PGF1-␣) levels. The study protocol was approved by an institutional animal research committee. All animals received humane care in compliance with the 'Guide for the Care and Use of Laboratory Animals'. All experiments conformed with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Experimental procedures
The atherosclerosis induction protocol has been described in detail elsewhere [11, 13] . Briefly [14] [15] [16] .
Aortic and hepatic tissue cholesterol content quantification
Aortic tissue cholesterol was determined always in the proximal half of the descending aorta harvested using a previously validated assay [17] 
Cholesterol content assays
The lipid content (10 6 [18, 19] . SDS-PAGE and Coomassie staining after ETC-216 delipidation revealed a single band in the apoA-I region (Fig. S1 ). 
Western blot analysis
Effect of rApoA-I Milano on the aortic vessel wall
The effects of the administration of rApoA-IM (a 5% of plaque regression and changes in lesion composition) have been previously reported [10] . Aortas of rApoA-IM-treated animals had significantly lower lipid content than those of placebo animals (Fig. 1,  upper 
Effect of rApoA-I Milano on the liver
The effects of rApoA-IM administration on the hepatic accumulation of cholesterol and liver expression of ABCA-1 and SR-BI were also assessed.
Recombinant-ApoA-IM dramatically reduced the hepatic cholesterol content of the livers versus those receiving placebo, Fig. 1, lower panel) 
Effect of different forms of apoA-I on macrophages' ABCA-1 and SR-BI density
Foam cells were generated by culture of macrophages with oxidized LDL. After 72 hrs of exposure to oxLDL, there was a dramatic ABCA-1 and SR-BI protein down-regulation, as noted above (Fig. S3). Treatment with both forms of apoA-I induced a significant up-regulation of both key receptors involved in RCT (ABCA-1 and SR-BI). Interestingly, macrophages' ABCA-1 and SR-BI density after treatment with the Milano form of apoA-I was significantly higher than after treatment with apoA-Iwt. See Fig. 6.
Discussion
We have previously reported the acute benefits associated with the administration of rApoA-IMilano to an experimental model of advanced atherosclerosis [10] . We are now describing the potential mechanisms responsible for the observed beneficial effects. [6] [7] [8] [9] [10] 20] . In the present study we are describing a significant reduction in aortic wall and hepatic cholesterol content and the up-regulation of ABCA-1 and SR-BI. These observations strongly suggest that the described benefits of rApoA-IM on plaque regression could, at least in part, be mediated via an enhanced RCT.
The main results of the present work are: (1) Two administrations of rApoA-IM in atherosclerotic rabbits resulted in a significant reduction of aortic and hepatic cholesterol content without affecting plasma cholesterol levels. (2) These observations were associated with a significant up-regulation of several of key players involved in the RCT (ABCA-1 and SR-BI) both at the vascular and hepatic level. (3) The administration of rApoA-IM resulted in a significant reduction of inflammatory markers and oxidative stress both at vascular (atherosclerotic lesion) and systemic (circulating) levels, suggesting a rescue of the global pro-inflammatory
E.M. of X-fold to housekeeping gene). Y-axis in the right panel corresponds to amount of RNA (expressed as mean Ϯ S.E.M. of X-fold to housekeeping gene).
The effects of rApoA-IM on the regression of previously established atherosclerotic lesions have been reported by different groups not only in experimental models but also in human beings
The present findings extend the previously described vasculoprotective effects of recombinant apoA-IM administration, providing insight into the mechanism of action. The effects of rApoA-IM administration on the removal of cholesterol from the established lesions is well documented [7, 8, 21] [24] , a recent study has challenged the involvement of macrophages SR-BI in RCT in vivo [25] .
Whether the Milano form of apoA-I is more effective than the wild-type in cholesterol removal has been the matter of heated discussion. Some reports claim that both forms are equally effective in their cholesterol removal and athero-protective activities [26, 27] , while others have shown that ApoA-IMilano is not only more effective in cholesterol removal [28, 29] 
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